A CONTROLLED TRIAL FOR EVALUATING 2 LIVE ATTENUATED MUMPS-MEASLES VACCINES (URABE AM 9-SCHWARZ AND JERYL-LYNN-MORATEN) IN YOUNG-CHILDREN
A CONTROLLED TRIAL FOR EVALUATING 2 LIVE ATTENUATED MUMPS-MEASLES VACCINES (URABE AM 9-SCHWARZ AND JERYL-LYNN-MORATEN) IN YOUNG-CHILDREN
复制标题
DOI：
10.1002/jmv.1890180109
复制
发表时间：
1986-01-01
影响因子：
12.7
通讯作者：
KUNZ, C
中科院分区：
文献类型：
--
作者：
POPOWKRAUPP, T;KUNDI, M;KUNZ, C
进行了一项前瞻性随机临床试验，以评估两种流行性腮腺炎-麻疹减毒活疫苗（Urabe Am 9- schwarz和Jeryl Lynn-Moraten疫苗）在400名9个月至4.5岁（中位13.4个月）的幼儿中的疗效。采用酶联免疫吸附试验（ELISA）测定对两种疫苗成分的抗体反应；接受Urabe Am - 9-Schwarz疫苗的血清阴性儿童中，96.9%的人表现出满意的腮腺炎抗体应答，而接受Jeryl Lynn-Moraten疫苗的儿童中，这一比例为90% （P < 0.01）。两组中产生麻疹病毒特异性抗体的比例相似，分别为98.5%和96.8%。这两种疫苗同样具有良好的耐受性和临床可接受性。
A prospective, randomised clinical trial was conducted to evaluate the efficacy of two live attenuated mumps-measles vaccines, the Urabe Am 9-Schwarz and the Jeryl Lynn-Moraten vaccine, in 400 young children aged 9 months-4.5 years (median 13.4 months). Antibody responses to both vaccine components were measured by the enzyme-linked immunosorbent assay (ELISA); 96.9% of the seronegative children who received the Urabe Am 9-Schwarz vaccine showed satisfactory mumps antibody responses compared to 90% of the Jeryl Lynn-Moraten vaccine recipients (P < .01). Similar proportions of both groups, 98.5% and 96.8%, respectively, developed measles virus specific antibodies. Both vaccines were equally well tolerated and clinically acceptable.